Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Financing Activities (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Cash from Financing Activities data on record, last reported at $449.4 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 9857.37% year-over-year to $449.4 million; the TTM value through Dec 2025 reached $561.7 million, up 69.14%, while the annual FY2025 figure was $561.7 million, 69.14% up from the prior year.
  • Cash from Financing Activities reached $449.4 million in Q4 2025 per OCUL's latest filing, up from $10.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $449.4 million in Q4 2025 and bottomed at -$1.2 million in Q1 2021.
  • Average Cash from Financing Activities over 5 years is $53.4 million, with a median of $3.4 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: crashed 109.07% in 2021, then soared 411724.36% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at $667000.0 in 2021, then tumbled by 31.33% to $458000.0 in 2022, then skyrocketed by 23517.9% to $108.2 million in 2023, then crashed by 95.83% to $4.5 million in 2024, then soared by 9857.37% to $449.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $449.4 million in Q4 2025, $10.4 million in Q3 2025, and $97.8 million in Q2 2025.